Send to

Choose Destination
Biotherapy. 1993;6(1):9-12.

Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study.

Author information

Service Onco-Hématologie, CHU de Hautepierre, Strasbourg, France.


Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium dithiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and 12 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center